| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | |
|---|---|---|---|---|
| Contract revenue | 0 | 0 | 172 | |
| Research and development | 3,221 | 5,505 | 6,570 | |
| General and administrative | 4,036 | 5,000 | 5,615 | |
| Total operating expenses | 7,257 | 10,505 | 12,185 | |
| Loss from operations | -7,257 | -10,505 | -12,013 | |
| Interest income and other, net | 68 | 158 | 218 | |
| Interest expense and other, net | 725 | 877 | 943 | |
| Net loss | -7,914 | -11,224 | -12,738 | |
| Net loss attributable to non-controlling interest | -2,502 | -4,532 | -5,474 | |
| Net loss attributable to rani therapeutics holdings, inc | -5,412 | -6,692 | -7,264 | |
| Net loss per class a common share attributable to rani therapeutics holding, inc., basic | -0.12 | -0.18 | -0.22 | |
| Net loss per class a common share attributable to rani therapeutics holding, inc., diluted | -0.12 | -0.18 | -0.22 | |
| Weighted average number of shares outstanding, basic | 46,444,000 | 36,542,000 | 33,440,000 | |
| Weighted average number of shares outstanding, diluted | 46,444,000 | 36,542,000 | 33,440,000 | |
Rani Therapeutics Holdings, Inc. (RANI)
Rani Therapeutics Holdings, Inc. (RANI)